nav-left cat-right
cat-right

Solvo, XenoBiotic to Provide In Vitro Transporter ...

XenoBiotic Laboratories established a partnership with Hungary-based Solvo Biotechnology to offer in vitro transporter services in the U.S. Solvo will transfer its efflux and uptake transporter assays to XBL’s research facilities in New Jersey. The services will be made available to American customers through both Solvo and XBL sales channels. Through this collaboration Solvo will be introducing GLP...

Affymetrix Launches Circulating Tumor Cell Platfor...

Affymetrix signed a worldwide distribution agreement for ScreenCell’s isolation devices and dilution buffers for the collection of circulating tumor cells (CTCs) in peripheral blood. The QuantiGene® ViewRNA CTC platform, which consists of ScreenCell’s products and Affymetrix’ QuantiGene ViewRNA Assays, is now available from Affymetrix. The arrangement makes Affymetrix the exclusive distributor of ScreenCell...

Four anti-cancer compounds identified

Sydney: Four new anti-cancer compounds have shown promise in inhibiting the growth of tumours, according to a new approach. Jason Smith, doing his M.Phil. in biomolecular sciences from Macquarie University, combined existing knowledge of an enzyme with computational chemistry approach to identify novel (cancer) inhibitors. The enzyme (indoleamine 2,3-dioxygenase) has generated excitement amongst researchers due to its...

Research at A&M and Scripps finds HIV-killing...

COLLEGE STATION – A powerful topical preventative for HIV, the virus that causes AIDS, could be a step closer to clinical trials, thanks to a newly discovered molecular compound that research at Texas A&M University and the Scripps Research Institute shows dissolves the virus on contact. The ability of the synthetic compound known as “PD 404,182” to break apart the AIDS-causing virus before it can...

First Clinical Trial of Autologous Cardiac Stem Ce...

Initial data from the first ever trial to evaluate autologous cardiac stem cell (CSC) transplants in humans suggests that the treatment improves left ventricular (LV) systolic function by an average of 12% over one year, and reduces infarct size in patients with severe heart failure due to ischemic heart disease. The trial investigators say the results triple the 4% average improvement that they had projected and calls...

FDA Clears Abbott’s Confirmatory Chagas Disease As...

FDA approved Abbott’s in vitro enzyme strip assay for Chagas disease. The Abbott ESA Chagastest detects antibodies to the causative pathogen Trypanosoma cruzi in serum or plasma samples. It is indicated for use as an additional, more specific test on human samples that have been found to be repeatedly reactive using a licensed screening test. The T. cruzi parasite is transmitted through contact with the feces of an...
Page 4 of 12« First...23456...10...Last »